<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01540760</url>
  </required_header>
  <id_info>
    <org_study_id>GA28006</org_study_id>
    <nct_id>NCT01540760</nct_id>
  </id_info>
  <brief_title>A Study of MCAF5352A in Healthy Volunteers</brief_title>
  <official_title>A Phase Ib, Single-Center, Randomized, Placebo-Controlled, Double-Blind Multiple Ascending-Dose Study to Investigate the Safety, Pharmacokinetics, and Immunogenicity of Subcutaneous MCAF5352A in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <brief_summary>
    <textblock>
      This single-center, randomized, placebo-controlled, double-blind, multiple ascending dose
      study will evaluate the safety, pharmacokinetics and immunogenicity of MCAF5352A in healthy
      volunteers. Subjects will be randomized to receive either MCAF5352A or placebo on Days 1, 15
      and 29.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: Incidence of adverse events</measure>
    <time_frame>approximately 5 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area under the concentration-time curve</measure>
    <time_frame>Pre-dose and 5 time points up to 14 days post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity: Serum MCAF5252A antibodies</measure>
    <time_frame>Days 1, 29, 50, 78, 106 and 134</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>MCAF5352A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MCAF5352A</intervention_name>
    <description>Multiple ascending doses</description>
    <arm_group_label>MCAF5352A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching MCAF5352A, multiple doses</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males and females, 18 - 55 years of age

          -  Subjects in good health as determined by screening medical history, physical
             examination, vital signs, 12-lead ECG and laboratory tests

          -  Body weight between 45 kg and 110 kg

          -  Female subjects must be willing to use two effective methods of contraception from
             screening to a minimum of 4 months after the last dose of study drug

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  Positive for hepatitis B, hepatitis C or HIV infection

          -  History of significant chronic or recurrent infections

          -  History of clinically significant drug allergy and/or a known hypersensitivity to
             protein therapeutics or formulation components or a related drug

          -  History of alcohol or drug abuse within 12 months prior to Day 1, or evidence of such
             abuse

          -  Subjects who have previously received the study drug

          -  Participation in a clinical trial within 4 weeks prior to Day 1 or use of any
             experimental or biologic therapy within 12 weeks prior to Day 1 or within 5 half-lives
             of the product, whichever is greater
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Genentech, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Quebec</city>
        <zip>G1P 0A2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2012</study_first_submitted>
  <study_first_submitted_qc>February 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 29, 2012</study_first_posted>
  <last_update_submitted>November 1, 2016</last_update_submitted>
  <last_update_submitted_qc>November 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

